LuciPral (Pralsetinib) 100mg*120 | Lucius Laos Generic | GLT

Generic Information: LuciPral (Pralsetinib) 100mg — Laos

LuciPral is a Lao-manufactured generic of pralsetinib from Lucius Pharmaceuticals (Lao) Co., Ltd., a Vientiane-based manufacturer with a broad portfolio of oncology generics for Southeast Asian and international patients. This listing is the 100 mg capsule in a larger 120-capsule pack — matching the originator's strength but in a convenient monthly supply at the standard dose. LuciPral offers a traceable, affordable alternative for RET-driven cancers.

Lucius Pharmaceuticals uses a distinctive "Luci" prefix across its oncology line, so buyers familiar with other Lucius products will recognise LuciPral as its pralsetinib offering. Because the standard dose is 400 mg once daily (four 100 mg capsules on an empty stomach), a 120-capsule pack of LuciPral covers a full 30-day month of treatment.

What Is LuciPral Used For?

LuciPral is indicated for RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancers, including RET-mutant medullary thyroid carcinoma (MTC), in patients requiring systemic therapy. These are rare, molecularly defined cancers identified by genetic testing, and pralsetinib is a selective RET inhibitor developed specifically for the RET-driven subset.

How Does LuciPral Work?

Pralsetinib, the active ingredient in LuciPral, selectively inhibits the RET receptor tyrosine kinase. In tumours with a RET fusion or mutation, the RET pathway is persistently activated and drives cancer cell growth and survival. LuciPral blocks this overactive pathway, interrupting the proliferative signal with a targeted mechanism that spares many of the toxicities of conventional chemotherapy.

Indications

• RET fusion-positive non-small cell lung cancer (NSCLC) requiring systemic therapy.
• RET-altered thyroid cancers, including RET-mutant medullary thyroid carcinoma (MTC), requiring systemic therapy.

Dosage and Administration

The recommended dose is 400 mg once daily, taken as four 100 mg capsules on an empty stomach — no food for at least 2 hours before and 1 hour after dosing. A 120-capsule pack provides 30 days of therapy. Dosing may be adjusted for adverse reactions, and blood pressure, liver function and blood counts are monitored during treatment.

Side Effects

Common adverse reactions include fatigue, constipation, musculoskeletal pain, hypertension, diarrhoea and elevated liver enzymes. Interstitial lung disease/pneumonitis is a serious risk requiring prompt reporting of respiratory symptoms. Blood pressure should be monitored, and patients should report any unusual bleeding or visual changes.

Storage

Store LuciPral below 30°C in the original pack, in a dry place away from direct light, and out of the reach of children. Use before the expiry date printed on the label.

Why Choose the GLT?

GLT sources LuciPral through a documented Lao supply chain and confirms each batch against the manufacturer's details before shipping. Lao generics of pralsetinib typically cost a fraction of the originator's US list price, making RET-targeted therapy sustainable for long-term treatment. We provide clear purchase documentation and direct contact for ongoing support.

How to Order LuciPral from GLT

To order LuciPral 100 mg (120 capsules), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and whether you require a prescription or purchase order. We confirm batch details and lead time before dispatch.

FAQ

Is LuciPral the same as Gavreto? LuciPral contains the same active ingredient (pralsetinib) at the same 100 mg strength as Gavreto; it is a generic manufactured in Laos by Lucius Pharmaceuticals.

How long does one pack last? At the standard 400 mg daily dose (four 100 mg capsules), a 120-capsule pack lasts 30 days.

Where can I order LuciPral? GLT can supply LuciPral internationally; reach us on WhatsApp or email for availability.